Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 22 studies | 38% ± 14% | |
| astrocyte | 16 studies | 44% ± 20% | |
| microglial cell | 13 studies | 48% ± 15% | |
| glutamatergic neuron | 12 studies | 49% ± 26% | |
| fibroblast | 12 studies | 34% ± 13% | |
| mast cell | 12 studies | 33% ± 10% | |
| GABAergic neuron | 11 studies | 47% ± 27% | |
| oligodendrocyte precursor cell | 11 studies | 47% ± 21% | |
| oligodendrocyte | 10 studies | 34% ± 13% | |
| pericyte | 9 studies | 25% ± 11% | |
| adipocyte | 9 studies | 30% ± 9% | |
| macrophage | 9 studies | 44% ± 17% | |
| smooth muscle cell | 8 studies | 31% ± 6% | |
| myeloid cell | 7 studies | 31% ± 12% | |
| epithelial cell | 7 studies | 40% ± 19% | |
| dendritic cell | 7 studies | 29% ± 7% | |
| ciliated cell | 7 studies | 28% ± 11% | |
| natural killer cell | 7 studies | 24% ± 5% | |
| endothelial cell of lymphatic vessel | 7 studies | 44% ± 10% | |
| regulatory T cell | 6 studies | 21% ± 5% | |
| T cell | 6 studies | 27% ± 6% | |
| neuron | 5 studies | 47% ± 23% | |
| retinal ganglion cell | 5 studies | 32% ± 16% | |
| amacrine cell | 5 studies | 34% ± 14% | |
| B cell | 5 studies | 24% ± 8% | |
| CD8-positive, alpha-beta T cell | 5 studies | 24% ± 6% | |
| cardiac muscle cell | 5 studies | 46% ± 11% | |
| type I pneumocyte | 5 studies | 28% ± 7% | |
| type II pneumocyte | 5 studies | 38% ± 8% | |
| monocyte | 5 studies | 33% ± 7% | |
| basal cell | 5 studies | 37% ± 21% | |
| interneuron | 5 studies | 61% ± 27% | |
| non-classical monocyte | 4 studies | 20% ± 3% | |
| mesothelial cell | 4 studies | 35% ± 8% | |
| lymphocyte | 4 studies | 34% ± 16% | |
| Mueller cell | 4 studies | 37% ± 12% | |
| retina horizontal cell | 4 studies | 28% ± 6% | |
| retinal cone cell | 4 studies | 37% ± 10% | |
| retinal rod cell | 4 studies | 40% ± 10% | |
| club cell | 4 studies | 32% ± 9% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 22% ± 3% | |
| classical monocyte | 3 studies | 22% ± 6% | |
| hematopoietic precursor cell | 3 studies | 21% ± 3% | |
| plasma cell | 3 studies | 22% ± 5% | |
| CD4-positive, alpha-beta T cell | 3 studies | 27% ± 3% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 24% ± 5% | |
| mononuclear phagocyte | 3 studies | 24% ± 3% | |
| vein endothelial cell | 3 studies | 43% ± 23% | |
| GABAergic amacrine cell | 3 studies | 34% ± 10% | |
| glycinergic amacrine cell | 3 studies | 33% ± 7% | |
| endothelial cell of vascular tree | 3 studies | 47% ± 22% | |
| retinal pigment epithelial cell | 3 studies | 47% ± 22% | |
| muscle cell | 3 studies | 44% ± 21% | |
| abnormal cell | 3 studies | 31% ± 18% | |
| ependymal cell | 3 studies | 45% ± 15% | |
| megakaryocyte-erythroid progenitor cell | 3 studies | 32% ± 7% | |
| respiratory goblet cell | 3 studies | 40% ± 14% | |
| alveolar macrophage | 3 studies | 36% ± 8% | |
| capillary endothelial cell | 3 studies | 29% ± 5% | |
| granule cell | 3 studies | 40% ± 17% | |
| leukocyte | 3 studies | 43% ± 5% | |
| kidney loop of Henle epithelial cell | 3 studies | 41% ± 20% | |
| renal principal cell | 3 studies | 48% ± 18% | |
| mural cell | 3 studies | 40% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| adrenal gland | 100% | 27212.93 | 258 / 258 | 100% | 48.30 | 230 / 230 |
| esophagus | 100% | 1697.87 | 1445 / 1445 | 100% | 25.58 | 183 / 183 |
| lung | 100% | 1606.41 | 578 / 578 | 100% | 29.47 | 1155 / 1155 |
| prostate | 100% | 1732.00 | 245 / 245 | 100% | 33.62 | 502 / 502 |
| thymus | 100% | 1475.88 | 653 / 653 | 100% | 31.75 | 604 / 605 |
| intestine | 100% | 1609.06 | 966 / 966 | 100% | 26.87 | 526 / 527 |
| bladder | 100% | 2005.38 | 21 / 21 | 100% | 29.93 | 503 / 504 |
| uterus | 100% | 2085.04 | 170 / 170 | 100% | 34.80 | 458 / 459 |
| ovary | 100% | 2101.56 | 180 / 180 | 100% | 40.61 | 429 / 430 |
| skin | 100% | 1668.77 | 1808 / 1809 | 100% | 34.10 | 471 / 472 |
| breast | 100% | 1785.25 | 459 / 459 | 100% | 34.01 | 1115 / 1118 |
| kidney | 100% | 2820.40 | 89 / 89 | 100% | 44.17 | 898 / 901 |
| brain | 100% | 1315.80 | 2633 / 2642 | 100% | 31.92 | 705 / 705 |
| stomach | 100% | 1264.06 | 359 / 359 | 100% | 26.17 | 285 / 286 |
| liver | 100% | 1003.62 | 225 / 226 | 100% | 23.14 | 406 / 406 |
| pancreas | 98% | 772.50 | 323 / 328 | 100% | 29.98 | 178 / 178 |
| adipose | 100% | 1836.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2202.65 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 50.49 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 36.81 | 29 / 29 |
| muscle | 100% | 2659.34 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1906.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 24.00 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 16.41 | 1 / 1 |
| peripheral blood | 99% | 1650.22 | 922 / 929 | 0% | 0 | 0 / 0 |
| heart | 99% | 2184.34 | 849 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006325 | Biological process | chromatin organization |
| GO_0010212 | Biological process | response to ionizing radiation |
| GO_0045739 | Biological process | positive regulation of DNA repair |
| GO_0006302 | Biological process | double-strand break repair |
| GO_0007165 | Biological process | signal transduction |
| GO_0006282 | Biological process | regulation of DNA repair |
| GO_0006974 | Biological process | DNA damage response |
| GO_0051301 | Biological process | cell division |
| GO_0007095 | Biological process | mitotic G2 DNA damage checkpoint signaling |
| GO_0044818 | Biological process | mitotic G2/M transition checkpoint |
| GO_0070536 | Biological process | protein K63-linked deubiquitination |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0006915 | Biological process | apoptotic process |
| GO_2000001 | Biological process | regulation of DNA damage checkpoint |
| GO_0071479 | Biological process | cellular response to ionizing radiation |
| GO_0005634 | Cellular component | nucleus |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0070531 | Cellular component | BRCA1-A complex |
| GO_0070552 | Cellular component | BRISC complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000152 | Cellular component | nuclear ubiquitin ligase complex |
| GO_0000268 | Molecular function | peroxisome targeting sequence binding |
| GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
| GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | BABAM2 |
| Protein name | Upstream ORF Alternative protein BRE BRISC and BRCA1-A complex member 2 (BRCA1-A complex subunit BRE) (BRCA1/BRCA2-containing complex subunit 45) (Brain and reproductive organ-expressed protein) BRISC and BRCA1-A complex member 2 |
| Synonyms | BRCC45 BRE |
| Description | FUNCTION: Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX . In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer . Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates . Within the BRISC complex, acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity . The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 . The BRISC complex plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression . Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination . May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect . . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . |
| Accessions | ENST00000344773.6 [Q9NXR7-1] Q9NXR7 ENST00000379629.7 F8W733 A0A075B7D2 ENST00000342045.6 [Q9NXR7-2] C9J2G0 ENST00000604932.1 Q96P08 L8E9D4 ENST00000436924.5 ENST00000379624.6 [Q9NXR7-2] ENST00000361704.6 [Q9NXR7-4] ENST00000379632.6 [Q9NXR7-4] |